News Archive

Fresenius Kabi’s Biosimilar Tyenne® (tocilizumab-aazg) becomes the first IV and Subcutaneous tocilizumab biosimilar approved by the FDA

Tyenne® provides a comprehensive, accessible, and high-quality treatment option for U.S. patients treated with tocilizumab.

IDACIO® (adalimumab-aacf) Now Available in the United States

Fresenius Kabi announced today the immediate availability in the U.S. of its citrate-free adalimumab biosimilar IDACIO® (adalimumab-aacf) for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira® (adalimumab).

CMS grants Fresenius Kabi permanent, product-specific Q-Code for Stimufend®  (pegfilgrastim-fpgk)

The approval of the adalimumab biosimilar, adalimumab-aacf, signals the beginning of Fresenius Kabi’s long-term dedication to biosimilars.

Stimufend® (pegfilgrastim-fpgk) Now Available in the United States

Fresenius Kabi announced today the immediate availability in the U.S. of Stimufend®(pegfilgrastim-fpgk), the company’s biosimilar to Neulasta® (pegfilgrastim), for use in patients at risk for febrile neutropenia

Biosimilar Adalimumab-aacf Gains FDA Approval, Marks Growing Interest in Biosimilar Development

The approval of the adalimumab biosimilar, adalimumab-aacf, signals the beginning of Fresenius Kabi’s long-term dedication to biosimilars.

Fresenius Kabi receives U.S. FDA approval for biosimilar Idacio® (adalimumab-aacf)

Fresenius Kabi receives U.S. FDA approval for biosimilar Stimufend® (pegfilgrastim-fpgk)

Fresenius Kabi joins the Biosimilars Forum

Fresenius Kabi USA Executive Discusses Pegfilgrastim Biosimilar Prospects